BCL2L1 and sarcoma: In line with our findings, co-inhibition of MCL-1 and BCL-xL showed stronger cytotoxicity in many sarcomas [57] and other cell lines, including those derived from colorectal cancer (CRC) [58] and cervical cancer [45], compared to co-inhibition of BCL-2/BCL-xL or MCL-1/BCL-2.